Application of Network Pharmacology and Molecular Docking to Explore the Mechanism of Danggui Liuhuang Tang against Hyperthyroidism


Citar

Texto integral

Resumo

Introduction:To investigate the mechanism of Danggui Liuhuang Tang (DGLHT) in the treatment of hyperthyroidism (HT), we explored the multi-component, multi-target, and multi-pathway mechanism based on the network pharmacology method of traditional Chinese medicine.

Objective:Using network pharmacology and molecular docking, the effective components, core targets, and critical pathways of DGLHT in the therapy of HT were investigated. The mechanism of DGLHT in the treatment of HT is discussed in this work, which also offers a scientific foundation for further research into the process.

Methods:To take DGLHT into the blood components as the research object, we used GeneCards, Drungbank, Therapeutic Target Database (TTD), Online Mendelian Inheritance in Man (OMIM), Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB), and other databases to predict the potential target of the components. Then, it was integrated with the predicted targets of HT disease to obtain the potential targets of DGLHT in the treatment of HT. We used String database and Cytoscape software for protein-protein interaction network (PPI) construction, and DAVID platform for Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation, the Cytoscape software was used to construct a \"component-target-pathway\" network; the AutoDock Vina platform was used to conduct molecular docking between the blood entry components and key targets.

Results:According to the analysis, a total of 93 active ingredients, 348 disease-related targets, and 36 potential targets were screened out. Among them, key targets such as MAPK1, CCND1, AKT1, and TNF exert curative effects, and the main pathways are the HIF-1 signaling pathway, FoxO signaling pathway, Chemokine signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, Jak-STAT signaling pathway, and other pathways. Molecular docking results verified the interaction between active ingredients and key targets, among which rustication and quercetin had high docking affinity with key target proteins MAPK1 and CCND1.

Conclusion:This study preliminary revealed that DGLHT has the characteristics of multi-component, multi-target, and multi-pathway in the treatment of HT, and it established a scientific foundation for a more detailed investigation of DGLHT's molecular mechanism in the treatment of HT.

Sobre autores

Dan Song

School of Information Science and Engineeringing, Zaozhuang University

Email: info@benthamscience.net

Bin Yang

School of Information Science and Engineering, Zaozhuang University

Autor responsável pela correspondência
Email: info@benthamscience.net

Wenzheng Bao

School of Information and Electrical Engineering, Xuzhou University of Technology

Autor responsável pela correspondência
Email: info@benthamscience.net

Jinglong Wang

College of Food Science and Pharmaceutical Engineering, Zaozhuang University

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Zimmermann, M.B.; Boelaert, K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol., 2015, 3(4), 286-295. doi: 10.1016/S2213-8587(14)70225-6 PMID: 25591468
  2. Taylor, P.N.; Albrecht, D.; Scholz, A.; Gutierrez-Buey, G.; Lazarus, J.H.; Dayan, C.M.; Okosieme, O.E. Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol., 2018, 14(5), 301-316. doi: 10.1038/nrendo.2018.18 PMID: 29569622
  3. Lillevang-Johansen, M.; Abrahamsen, B.; Jørgensen, H.L.; Brix, T.H.; Hegedüs, L. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Thyroid, 2019, 29(3), 332-340. doi: 10.1089/thy.2018.0320 PMID: 30648498
  4. Khan, R.; Sikanderkhel, S.; Gui, J.; Adeniyi, A.R.; O’Dell, K.; Erickson, M.; Malpartida, J.; Mufti, Z.; Khan, T.; Mufti, H.; Al-Adwan, S.A.; Alvarez, D.; Davis, J.; Pendley, J.; Patel, D. Thyroid and cardiovascular disease: A focused review on the impact of hyperthyroidism in heart failure. Cardiol. Res., 2020, 11(2), 68-75. doi: 10.14740/cr1034 PMID: 32256913
  5. Ramadan, H.M.; Taha, N.A.; Ahmed, H.H. Melatonin enhances antioxidant defenses but could not ameliorate the reproductive disorders in induced hyperthyroidism model in male rats. Environ. Sci. Pollut. Res. Int., 2021, 28(4), 4790-4804. doi: 10.1007/s11356-020-10682-7 PMID: 32951169
  6. Zygmunt, A.; Krawczyk-Rusiecka, K.; Skowrońska-Jóźwiak, E.; Wojciechowska-Durczyńska, K.; Głowacka, E.; Adamczewski, Z.; Lewiński, A. The effect of recombinant human TSH on sclerostin and other selected bone markers in patients after total thyroidectomy for differentiated thyroid cancer. J. Clin. Med., 2021, 10(21), 4905. doi: 10.3390/jcm10214905 PMID: 34768424
  7. Scappaticcio, L.; Longo, M.; Maiorino, M.I.; Pernice, V.; Caruso, P.; Esposito, K.; Bellastella, G. Abnormal liver blood tests in patients with hyperthyroidism: Systematic review and meta-analysis. Thyroid, 2021, 31(6), 884-894. doi: 10.1089/thy.2020.0715 PMID: 33327837
  8. Shen, X.; Yang, R.; An, J.; Zhong, X. Analysis of the molecular mechanisms of the effects of prunella vulgaris against subacute thyroiditis based on network pharmacology. Evid. Based Complement. Alternat. Med., 2020, 2020(8), 1-13. doi: 10.1155/2020/9810709 PMID: 33273957
  9. Zhou, M.; Hong, Y.; Lin, X.; Shen, L.; Feng, Y. Recent pharmaceutical evidence on the compatibility rationality of traditional Chinese medicine. J. Ethnopharmacol., 2017, 206, 363-375. doi: 10.1016/j.jep.2017.06.007 PMID: 28606807
  10. Deng, C.; Li, J.; Tanf, X.Z. Observation of the short-term effects and long-term recurrence rate of chaihu shugan san in the treatment of hyperthyroidism thyroid function. Liaoning Zhongyiyao Daxue Xuebao, 2017, 19(6), 107-110.
  11. Xu, N.; He, X.J.; Gang, X.L.; Fu, L.P. Huangqi suanzaoren decoction in treatment of hyperthyroidism. Acta. Chinese. Med., 2019, 34(249), 375-378.
  12. Guo, J.L. 50 Cases with hyperthyroidism treated by sour jujube decoction combined with minor bupleurum decoction. Henan Traditional Chinese Medicine, 2015, 35(2), 234-236.
  13. Yang, K.; Guo, K.Q.; Wu, H.Y.; Ye, L.X.; Xia, H. Clinical effect of prunrllae oral solution in treating hyperthyrea. Z red fruit Z red medicine za value, 2007, 32(16), 1706-1708. PMID: 18027674
  14. Sun, F.; Ruan, Z.H. Therapeutic effect of danggui liuhuang decoction on hyperthyroidism of phlegm and blood stasis type. J. Trad. Chin. Med., 2019, 33(10), 27-29.
  15. Xu, Y.J. Application of danggui liuhuang decoction in diabetes complications. Liaoning J Trad Chinese Med, 2011, 38(9), 1889-1890.
  16. Zhang, Y. Clinical observation of danggui liuhuang decoction in the treatment of perimenopausal syndrome. J North Pharm, 2018, 15(3), 57.
  17. Li, J.W.; Wang, D.C.; Wu, H.B.; Lin, J.W.; Song, X.R.; Cheng, B.M. Systematic evaluation and meta-analysis of modified danggui liuhuang decoction combined with antithyroid drugs in the treatment of hyperthyroidism. J Guangzhou Uni Trad Chinese Med, 2021, 38(02), 426.
  18. Ruan, D.Y.; Guo, X.X. Effect of modified dangguiliuhuang decoction combined with methimazole on patients with yin deficiency and fire hyperthyroidism. Pract Clin J Trad Chin Med, 2021, 21(16), 17.
  19. Lu, W.F. 30 Cases of yin deficiency and fire hyperthyroidism treated by danggui liuhuang decoction combined with propyl thiouracil. Chin J Ethnomed Ethnopharm, 2018, 07(09), 83.
  20. Zen, X.X.; Yuan, Y.; Liu, Y.; Wu, T.X.; Han, S. Chinese herbal medicines for hyperthyroidism. Cochrane Database Syst. Rev., 2007, 2007(2), CD005450. PMID: 17443591
  21. Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; Xu, X.; Li, Y.; Wang, Y.; Yang, L. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform., 2014, 6(1), 13. doi: 10.1186/1758-2946-6-13 PMID: 24735618
  22. Tian, S.; Wang, J.; Li, Y.; Li, D.; Xu, L.; Hou, T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv. Drug Deliv. Rev., 2015, 86, 2-10. doi: 10.1016/j.addr.2015.01.009 PMID: 25666163
  23. Xiong, G.; Wu, Z.; Yi, J.; Fu, L.; Yang, Z.; Hsieh, C.; Yin, M.; Zeng, X.; Wu, C.; Lu, A.; Chen, X.; Hou, T.; Cao, D. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res., 2021, 49(W1), W5-W14. doi: 10.1093/nar/gkab255 PMID: 33893803
  24. Szklarczyk, D.; Morris, J.H.; Cook, H.; Kuhn, M.; Wyder, S.; Simonovic, M.; Santos, A.; Doncheva, N.T.; Roth, A.; Bork, P.; Jensen, L.J.; von Mering, C. The STRING database in 2017: Quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res., 2017, 45(D1), D362-D368. doi: 10.1093/nar/gkw937 PMID: 27924014
  25. Chen, G.; Seukep, A.J.; Guo, M. Recent advances in molecular docking for the research and discovery of potential marine drugs. Mar. Drugs, 2020, 18(11), 545. doi: 10.3390/md18110545 PMID: 33143025
  26. Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des., 2010, 24(5), 417-422. doi: 10.1007/s10822-010-9352-6 PMID: 20401516
  27. Hsin, K.Y.; Ghosh, S.; Kitano, H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS One, 2013, 8(12), e83922. doi: 10.1371/journal.pone.0083922 PMID: 24391846
  28. Qian, H.; Jin, Q.; Liu, Y.; Wang, N.; Chu, Y.; Liu, B.; Liu, Y.; Jiang, W.; Song, Y. Study on the multitarget mechanism of sanmiao pill on gouty arthritis based on network pharmacology. Evid. Based Complement. Alternat. Med., 2020, 2020, 1-11. doi: 10.1155/2020/9873739 PMID: 32831884
  29. Panda, S.; Kar, A. Annona squamosa seed extract in the regulation of hyperthyroidism and lipid-peroxidation in mice: Possible involvement of quercetin. Phytomedicine, 2007, 14(12), 799-805. doi: 10.1016/j.phymed.2006.12.001 PMID: 17291737
  30. Zhao, P.; Hu, Z.; Ma, W.; Zang, L.; Tian, Z.; Hou, Q. Quercetin alleviates hyperthyroidism‐induced liver damage via Nrf2 Signaling pathway. Biofactors, 2020, 46(4), 608-619. doi: 10.1002/biof.1626 PMID: 32078205
  31. Araujo, A.S.R.; Schenkel, P.; Enzveiler, A.T.; Fernandes, T.R.G.; Partata, W.A.; Llesuy, S.; Ribeiro, M F M.; Khaper, N.; Singal, P.K.; Belló-Klein, A. The role of redox signaling in cardiac hypertrophy induced by experimental hyperthyroidism. J. Mol. Endocrinol., 2008, 41(6), 423-430. doi: 10.1677/JME-08-0024 PMID: 18787053
  32. Díez, J.J.; Hernanz, A.; Medina, S.; Bayón, C.; Iglesias, P. Serum concentrations of tumour necrosis factor-alpha (TNF-α) and soluble TNF-α receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin. Endocrinol., 2002, 57(4), 515-521. doi: 10.1046/j.1365-2265.2002.01629.x PMID: 12354134
  33. Leal, A.L.R.C.; Pantaleão, T.U.; Moreira, D.G.; Marassi, M.P.; Pereira, V.S.; Rosenthal, D.; Corrêa da Costa, V.M. Hypothyroidism and hyperthyroidism modulates Ras-MAPK intracellular pathway in rat thyroids. Endocrine, 2007, 31(2), 174-178. doi: 10.1007/s12020-007-0029-4 PMID: 17873330
  34. Wang, Q.H. Research on professor Lin Lan’s clinical experience in the treatment of hyperthyroidism and the mechanism of JiaKangning capsule in regulating of ERK pathway in FRTL-5 cells; Chinese Academy of Traditional Chinese Medicine, 2016.
  35. Agretti, P.; De Marco, G.; Ferrarini, E.; Di Cosmo, C.; Montanelli, L.; Bagattini, B.; Chiovato, L.; Tonacchera, M. Gene expression profile in functioning and non-functioning nodules of autonomous multinodular goiter from an area of iodine deficiency: Unexpected common characteristics between the two entities. J. Endocrinol. Invest., 2022, 45(2), 399-411. doi: 10.1007/s40618-021-01660-y PMID: 34405392
  36. Polak, A.; Grywalska, E.; Klatka, J.; Roliński, J.; Matyjaszek-Matuszek, B.; Klatka, M. Toll-Like Receptors-2 and -4 in graves’ disease-key players or bystanders? Int. J. Mol. Sci., 2019, 20(19), 4732. doi: 10.3390/ijms20194732 PMID: 31554206
  37. Aktaş, T.; Celik, S.K.; Genc, G.C.; Arpaci, D.; Can, M.; Dursun, A. Higher levels of serum TLR2 and TLR4 in patients with hashimoto’s thyroiditis. Endocr. Metab. Immune Disord. Drug Targets, 2020, 20(1), 118-126. doi: 10.2174/1871530319666190329114621 PMID: 30924423
  38. Fallahi, P.; Ferrari, S.M.; Elia, G.; Ragusa, F.; Paparo, S.R.; Patrizio, A.; Camastra, S.; Miccoli, M.; Cavallini, G.; Benvenga, S.; Antonelli, A. Cytokines as targets of novel therapies for graves’ ophthalmopathy. Front. Endocrinol., 2021, 12, 654473. doi: 10.3389/fendo.2021.654473 PMID: 33935970
  39. Wei, Y.H.; Liao, S.L.; Wang, C.C.; Wang, S.H.; Tang, W.C.; Yang, C.H. Simvastatin inhibits CYR61 expression in orbital fibroblasts in graves’ ophthalmopathy through the regulation of FoxO3a signaling. Mediators Inflamm., 2021, 2021, 1-12. doi: 10.1155/2021/8888913 PMID: 33542676
  40. Taglieri, L.; Nardo, T.; Vicinanza, R.; Ross, J.M.; Scarpa, S.; Coppotelli, G. Thyroid hormone regulates fibronectin expression through the activation of the hypoxia inducible factor 1. Biochem. Biophys. Res. Commun., 2017, 493(3), 1304-1310. doi: 10.1016/j.bbrc.2017.09.169 PMID: 28974422
  41. Endo, T. Thyrotropin receptor-structure, autoantibody and signal transduction. Jpn. J. Clin. Med., 2006, 64(12), 2203-2207. PMID: 17154079
  42. Cui, X.; Huang, M.; Wang, S.; Zhao, N.; Huang, T.; Wang, Z.; Qiao, J.; Wang, S.; Shan, Z.; Teng, W.; Li, Y. Circulating exosomes from patients with graves’ disease induce an inflammatory immune response. Endocrinology, 2021, 162(3), bqaa236. doi: 10.1210/endocr/bqaa236 PMID: 33367747

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024